The overview discusses 58 peptides in numerous clinical phases, indicating a robust pipeline of peptide therapies targeting PPIs. Co-formulation with other permeation enhancers, enzyme inhibitors, and hydrogels have also been used to enable the oral administration of other peptide medications, like octreotide and insulin, which are now in clinical trials280,281. https://alexandery048xsx6.blogsidea.com/profile